Five‐year EFS was 36.9% for patients who underwent complete resection, whereas no patient with unresectable tumor achieved 5‐year EFS; 5‐year OS rates for these 2 subgroups were 55.7% and 52%, respectively. The group of patients with embryonal, alveolar, or NOS RMS included 110 patients with complete data regarding clinical findings, treatment, and outcome. Asia-Pacific Journal of Clinical Oncology. At the American Cancer Society, we’re on a mission to free the world from cancer. Regional node involvement was classified as N0 or N1, and distant metastases were classified at onset as M0 or M1, based on histologic or clinical/radiologic assessment.6 The IRS system categorizes patients into one of four groups based on the amount and extent of residual tumor after the initial surgical procedure: Group I includes completely excised tumors with negative microscopic margins; Group II includes macroscopically resected tumors with microscopic residual disease and/or regional lymph node spread; Group III includes patients with macroscopic residual disease after incomplete resection or biopsy; and Group IV includes patients with metastases at onset.7. Patient-derived orthotopic xenograft models of sarcoma. For reprint requests, please see our Content Usage Policy. Currently, more than 70% of children with localized RMS can be cured with multidisciplinary treatment protocols that include chemotherapy.2 In contrast, standard treatment for adults with localized soft tissue sarcoma is based on surgery, often complemented by radiotherapy. This study examines short-term outcomes using doxorubicin, ifosfamide, and vincristine for adult rhabdomyosarcoma. In all cases, pathologic diagnosis was made before the start of treatment by pathologists at our institution, according to standard diagnostic criteria.4, 5 The botryoid variant of RMS was included in the embryonal subtype for the current analysis. The total dose ranged from 35 to 66 Gy, with a median dose of 54 Gy. Patients in the current series were treated in the last 25 years; during this time, multiagent systemic treatment has been readily available at a referral European institution for sarcomas that have been involved in pediatric RMS trials. In some cases it may shrink the tumor enough that surgery can remove the remaining tumor completely. Until we do, we’ll be funding and conducting research, sharing expert information, supporting patients, and spreading the word about prevention. Overall, 109 patients received radiotherapy. Still, the observation of similar results in a distinct subgroup in the current series indicates that the question posed by the current study is worth answering. Consensus and controversies regarding the treatment of rhabdomyosarcoma. Next article in issue: The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma . This response rate substantially differs from the rate observed in adults with soft tissue spindle cell sarcomas (response rate < 50%) and clearly falls in the same range as the rate for pediatric small cell sarcomas (i.e., RMS and Ewing family tumors). Patient age ranged from 19 to 83 years, with a median of 27 years. The American Cancer Society is a qualified 501(c)(3) tax-exempt organization. The percentage of patients with a score of 1 varied across age groups: among patients ages 19–30 years, 45% had a score of 1, compared with 29% of patients older than age 30 years. Even uncontrolled studies of adults could be useful, provided that they are designed in a way that makes them suitable for confirming the applicability in another age group, through specific treatment solutions, of principles established in large, controlled trials in pediatric populations. Statewide Treatment Center Referral Patterns for Adolescent and Young Adult Patients with Cancer in Utah. Objective: Rhabdomyosarcoma (RMS) in adults is a rare malignancy. Help make it a reality. Of the 37 patients who did not receive radiotherapy as front‐line treatment, 5 did not do so because of early progression and 2 refused treatment.